Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 agonists in clinical use with more in development. GLP-1 treatment typically can induce a lowering of hemoglobin A1c (HbA1c...
Main Authors: | Sri Harsha Tella, Marc S. Rendell |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-06-01
|
Series: | Therapeutic Advances in Endocrinology and Metabolism |
Online Access: | https://doi.org/10.1177/2042018815580257 |
Similar Items
-
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
by: Kira B. Harris, et al.
Published: (2015-02-01) -
The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
by: Kira R. Brice, et al.
Published: (2011-01-01) -
Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
by: O K Vikulova, et al.
Published: (2018-06-01) -
Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Young Min Cho, et al.
Published: (2013-12-01) -
Heart and mind: The story of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus
by: Djordje S Popovic
Published: (2020-01-01)